These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 22898113)
1. The therapeutic potential of pharmacological chaperones and proteosomal inhibitors, Celastrol and MG132 in the treatment of sialidosis. O'Leary EM; Igdoura SA Mol Genet Metab; 2012 Sep; 107(1-2):173-85. PubMed ID: 22898113 [TBL] [Abstract][Full Text] [Related]
2. Five novel mutations in the lysosomal sialidase gene (NEU1) in type II sialidosis patients and assessment of their impact on enzyme activity and intracellular targeting using adenovirus-mediated expression. Pattison S; Pankarican M; Rupar CA; Graham FL; Igdoura SA Hum Mutat; 2004 Jan; 23(1):32-9. PubMed ID: 14695530 [TBL] [Abstract][Full Text] [Related]
3. Mutations in sialidosis impair sialidase binding to the lysosomal multienzyme complex. Lukong KE; Landry K; Elsliger MA; Chang Y; Lefrancois S; Morales CR; Pshezhetsky AV J Biol Chem; 2001 May; 276(20):17286-90. PubMed ID: 11279074 [TBL] [Abstract][Full Text] [Related]
5. Ganglioside GM3 sialidase activity in fibroblasts of normal individuals and of patients with sialidosis and mucolipidosis IV. Subcellular distribution and and some properties. Lieser M; Harms E; Kern H; Bach G; Cantz M Biochem J; 1989 May; 260(1):69-74. PubMed ID: 2775195 [TBL] [Abstract][Full Text] [Related]
6. Characterization of the sialidase molecular defects in sialidosis patients suggests the structural organization of the lysosomal multienzyme complex. Lukong KE; Elsliger MA; Chang Y; Richard C; Thomas G; Carey W; Tylki-Szymanska A; Czartoryska B; Buchholz T; Criado GR; Palmeri S; Pshezhetsky AV Hum Mol Genet; 2000 Apr; 9(7):1075-85. PubMed ID: 10767332 [TBL] [Abstract][Full Text] [Related]
7. Biochemical and molecular characterization of novel mutations in GLB1 and NEU1 in patient cells with lysosomal storage disorders. Kwak JE; Son MY; Son YS; Son MJ; Cho YS Biochem Biophys Res Commun; 2015 Feb; 457(4):554-60. PubMed ID: 25600812 [TBL] [Abstract][Full Text] [Related]
8. Splice donor site mutation in the lysosomal neuraminidase gene causing exon skipping and complete loss of enzyme activity in a sialidosis patient. Penzel R; Uhl J; Kopitz J; Beck M; Otto HF; Cantz M FEBS Lett; 2001 Jul; 501(2-3):135-8. PubMed ID: 11470272 [TBL] [Abstract][Full Text] [Related]
9. Elimination of abnormal sialylglycoproteins in fibroblasts with sialidosis and galactosialidosis by normal gene transfer and enzyme replacement. Oheda Y; Kotani M; Murata M; Sakuraba H; Kadota Y; Tatano Y; Kuwahara J; Itoh K Glycobiology; 2006 Apr; 16(4):271-80. PubMed ID: 16361247 [TBL] [Abstract][Full Text] [Related]
10. Modeling Sialidosis with Neural Precursor Cells Derived from Patient-Derived Induced Pluripotent Stem Cells. Seol B; Kim YD; Cho YS Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922276 [TBL] [Abstract][Full Text] [Related]
11. Thymoquinone from nutraceutical black cumin oil activates Neu4 sialidase in live macrophage, dendritic, and normal and type I sialidosis human fibroblast cells via GPCR Galphai proteins and matrix metalloproteinase-9. Finlay TM; Jayanth P; Amith SR; Gilmour A; Guzzo C; Gee K; Beyaert R; Szewczuk MR Glycoconj J; 2010 Apr; 27(3):329-48. PubMed ID: 20213245 [TBL] [Abstract][Full Text] [Related]
12. Clinical variability of type II sialidosis by C808T mutation. Rodríguez Criado G; Pshezhetsky AV; Rodríguez Becerra A; Gómez de Terreros I Am J Med Genet A; 2003 Feb; 116A(4):368-71. PubMed ID: 12522793 [TBL] [Abstract][Full Text] [Related]
13. Novel missense mutations in the human lysosomal sialidase gene in sialidosis patients and prediction of structural alterations of mutant enzymes. Itoh K; Naganawa Y; Matsuzawa F; Aikawa S; Doi H; Sasagasako N; Yamada T; Kira J; Kobayashi T; Pshezhetsky AV; Sakuraba H J Hum Genet; 2002; 47(1):29-37. PubMed ID: 11829139 [TBL] [Abstract][Full Text] [Related]
14. Generation of human induced pluripotent stem cells (hIPSCs) from sialidosis types I and II patients with pathogenic neuraminidase 1 mutations. Han MJ; Annunziata I; Weesner J; Campos Y; Salie M; O'Reilly C; d'Azzo A Stem Cell Res; 2020 Jul; 46():101836. PubMed ID: 32485644 [TBL] [Abstract][Full Text] [Related]
15. Cloning, expression and chromosomal mapping of human lysosomal sialidase and characterization of mutations in sialidosis. Pshezhetsky AV; Richard C; Michaud L; Igdoura S; Wang S; Elsliger MA; Qu J; Leclerc D; Gravel R; Dallaire L; Potier M Nat Genet; 1997 Mar; 15(3):316-20. PubMed ID: 9054950 [TBL] [Abstract][Full Text] [Related]
16. Novel mutations in lysosomal neuraminidase identify functional domains and determine clinical severity in sialidosis. Bonten EJ; Arts WF; Beck M; Covanis A; Donati MA; Parini R; Zammarchi E; d'Azzo A Hum Mol Genet; 2000 Nov; 9(18):2715-25. PubMed ID: 11063730 [TBL] [Abstract][Full Text] [Related]
17. In silico identification of new putative pathogenic variants in the NEU1 sialidase gene affecting enzyme function and subcellular localization. Bonardi D; Ravasio V; Borsani G; d'Azzo A; Bresciani R; Monti E; Giacopuzzi E PLoS One; 2014; 9(8):e104229. PubMed ID: 25153125 [TBL] [Abstract][Full Text] [Related]
18. Lysosomal and plasma membrane ganglioside GM3 sialidases of cultured human fibroblasts. Differentiation by detergents and inhibitors. Schneider-Jakob HR; Cantz M Biol Chem Hoppe Seyler; 1991 Jun; 372(6):443-50. PubMed ID: 1910582 [TBL] [Abstract][Full Text] [Related]
19. Mucolipidosis I--a sialidosis. Sphranger J; Gehler J; Cantz M Am J Med Genet; 1977; 1(1):21-9. PubMed ID: 610423 [TBL] [Abstract][Full Text] [Related]
20. AAV-mediated gene therapy for sialidosis. van de Vlekkert D; Hu H; Weesner JA; Fremuth LE; Brown SA; Lu M; Gomero E; Campos Y; Sheppard H; d'Azzo A Mol Ther; 2024 Jul; 32(7):2094-2112. PubMed ID: 38796704 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]